Home › NDC Lookup › Ingredients › Tamsulosin Hydrochloride › 76282-0744-05

Tamsulosin hydrochloride .4 mg Capsule, 500-count

by EXELAN PHARMACEUTICALS, INC. · 500 CAPSULE in 1 BOTTLE (76282-744-05)

NDC 76282-0744-05

🏷️ FDA NDC (as labeled) 76282-744-05 billing pads the product segment with a zero

This package

Contains500-count Cost per ea$0.0509 NADAC Per package$25.45 / 500 capsules Pack sizes2 compare ↓

Also priced by: Medicaid pays $0.3298/unit · Part D plans $0.1304/unit — full pricing hub ↓

Also comes in: 90 capsules 76282-0744-90

Rx only Generic On market Non-controlled

🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm

📋 All sources & update times →

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 76282-744-05

Product NDC 76282-744

11-digit billing NDC 76282074405

NCPDP billing unit EA — each (per item)

RxCUI 863669

UNII 11SV1951MR

Application # ANDA078801

SPL Set ID db6cb771-2cff-40b7-a5ef-ea3cf2a3b461

Established class (EPC) alpha-Adrenergic Blocker

Mechanism of action Adrenergic alpha-Antagonists

DEA schedule Non-controlled

Marketing category ANDA

Marketing status On market

FDA listing status Listed (active directory)

Marketing start 2024-03-01

Route ORAL

Dosage form CAPSULE

Substance TAMSULOSIN HYDROCHLORIDE

GPI-14 56852070100110

GCN Seq No 027546

GCN 48191

HICL code 013864

Ingredient (HICL) Tamsulosin Hcl

HIC1 code Q

Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other

HIC2 code Q9

Therapeutic class — intermediate (HIC2) Urological Preparations

HIC3 code Q9B

Therapeutic class — specific (HIC3) Benign Prostatic Hypertrophy/Micturition Agents

AHFS code 12:16.04.12

AHFS class Selective Alpha-1-Adrenergic Block.agent

FDB label name TAMSULOSIN HCL 0.4 MG CAPSULE

FDB brand name Tamsulosin Hcl

Legend status F — Federal legend — prescription drug or device

TE code (Orange Book) AB · RLD · RS

Why two NDCs? The FDA registers this code as 76282-744-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 76282-0744-05. Same drug, same package — only the format differs.

Where does this data come from?

Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the alpha-Adrenergic Blocker class.

Pharmacologic class alpha-Adrenergic Blocker

Drug family (ATC) Alpha-adrenoreceptor antagonists

How it works Adrenergic alpha-Antagonists

Where does this data come from?

Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerEXELAN PHARMACEUTICALS, INC.

Application holderSYNTHON BV

FDA applicationANDA078801 (ANDA)

Labeler code76282

First marketedMar 2024

Product typeHuman Prescription Drug

Portfolio78 products on file

🔎 All NDCs from EXELAN PHARMACEUTICALS, INC.

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).

Where does this data come from?

Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name TAMSULOSIN HCL 0.4 MG CAPSULE Ingredient Tamsulosin Hcl

📖 What it is MedlinePlus · NLM

Tamsulosin is used to treat benign prostatic hyperplasia (BPH; enlarged prostate that can cause difficulty urinating, painful urination or increased urinary frequency or urgency). Tamsulosin is in a class of medications called alpha blockers. It works by relaxing the muscles in the prostate and bladder so that urine can flow easily.

Read the full MedlinePlus article ↗

📗 Our plain-language guide HelloPharmacist

Tamsulosin is designed to ease the urinary symptoms caused by an enlarged prostate — things like a weak stream, straining to start, or feeling like you haven't fully emptied your b...
What exactly is tamsulosin supposed to do for me?
Take it once a day, about 30 minutes after the same meal each day — for example, every morning after breakfast. Consistency matters here. Swallow the capsule whole; don't crush, ch...
It can, yes — this is one of the more common side effects, and it's worth knowing about upfront. Some men notice reduced ejaculation volume or what's called retrograde ejaculation,...

📖 Read our full Tamsulosin guide →

Patient education

📘 MedlinePlus patient leaflet ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →

Where does this data come from?

Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color green / orange

Shapecapsule

ImprintTSL;0;4

Size19 mm

ScoringNot scored

One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.

Where does this data come from?

Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

UNII 54S68520I4
A positively charged chemical form of ammonia, ammonium helps balance the acidity or alkalinity of a medicine and may assist in dissolving or stabilizing other ingredients.
UNII 8PJ61P6TS3
Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
UNII 3K9958V90M
A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
UNII L06K8R7DQK
A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
UNII 1K09F3G675
Ferric oxide red is an inorganic iron compound used as a colorant in medicines. It gives tablets, capsules, or other dosage forms a red or reddish tint for identification and appearance.
UNII EX438O2MRT
Ferric oxide yellow is a naturally occurring iron compound used as a colorant in medications. It gives tablets, capsules, and other forms a yellow or golden hue for identification and appearance.
UNII XM0M87F357
A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
UNII 2G86QN327L
Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
UNII ND2M416302
Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
UNII NX76LV5T8J
A synthetic plastic polymer made from methacrylic acid and ethyl acrylate. It's used as a coating or binder to control how and where the medicine dissolves in your digestive system.
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
UNII WZH3C48M4T
Potassium hydroxide is a strong alkaline chemical used in medicines to adjust and maintain the pH level of liquid formulations, helping keep the product stable and the active ingredients effective.
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
UNII 46N107B71O
Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
UNII 7SEV7J4R1U
A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
UNII 8Z96QXD6UM
Triethyl citrate is a clear liquid derived from citric acid. It acts as a plasticizer and solvent in tablet coatings and film formulations, helping the coating remain flexible and adhere properly to the medicine.
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

18 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?

Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?

No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.

Why might an inactive ingredient be missing?

Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.

Can inactive ingredients matter?

Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price system	Per ea	Per package
Retail pharmacies payNADAC · weekly	$0.051	$25.45 / 500 capsules
Medicaid paysCMS SDUD · 12 mo	$0.3298	$164.90 / 500 capsules
Medicare drug plans payPart D · Q2 2026	$0.1304	$65.20 / 500 capsules

NADAC price history (per ea) — tap or hover for the price & month

▼ Down 1% over the last 9 months.

Where does this data come from?

NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

Product	Labeler	Pack	NADAC/unit	TE	Status	Price vs. this
Tamsulosin Hydrochloride .4 mg 00904-7383-61	Major	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 50268-0740-15	AvPAK	50 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 57237-0014-01	Rising	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 62135-0775-30	Chartwell	30 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 65862-0598-01	Aurobindo	100 capsules	$0.051	—	Availability likely	—
Tamsulosin Hydrochloride .4 mg 67877-0450-01	Ascend	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 68084-0299-01	American	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 68382-0132-01	Zydus	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 72603-0115-01	NorthStar	100 capsules	$0.051	AB	Availability likely	—
Tamsulosin hydrochloride .4 mgthis 76282-0744-05	EXELAN	500 capsules	$0.051	AB	Availability likely	—
Tamsulosin Hydrochloride .4 mg 82009-0025-10	Quallent	1000 capsules	$0.051	AB	Availability likely	—
tamsulosin hydrochloride .4 mg 00781-2076-01	Sandoz	100 capsules	$0.054	—	FDA listed	+6%
Tamsulosin Hydrochloride .4 mg 00115-8211-01	Amneal	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 00615-8055-05	NCS	15 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 33342-0159-07	Macleods	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 42291-0989-10	AvKARE	1000 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 43063-0725-30	PD-Rx	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 43063-0947-30	PD-Rx	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-1846-00	A-S	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-3646-00	A-S	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-4906-00	A-S	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-5553-00	A-S	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-6699-00	A-S	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 50090-6700-00	A-S	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 51407-0879-90	Golden	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 51655-0832-52	Northwind	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 55154-2142-00	Cardinal	10 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 55154-2636-00	Cardinal	10 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 60760-0598-90	St.	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 61919-0703-90	DIRECT	5904900000 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 62756-0160-08	Sun	100 capsules	—	—	FDA listed	—
Tamsulosin Hydrochloride .4 mg 63187-0358-07	Proficient	7 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 63187-0371-07	Proficient	7 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 63187-0469-30	Proficient	30 capsules	—	—	FDA listed	—
Tamsulosin Hydrochloride .4 mg 63629-4346-01	Bryant	30 capsules	—	AB	FDA listed	—
Tamsulosin hydrochloride .4 mg 63672-0021-09	Synthon	20000 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 65841-0695-01	Zydus	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 67046-1015-03	Coupler	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 67296-2220-01	Redpharm	7 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68071-1840-01	NuCare	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68071-2561-01	NuCare	10 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68071-4443-01	NuCare	10 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68071-4872-09	NuCare	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68071-5118-01	NuCare	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68788-7050-01	Preferred	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 70518-0179-00	REMEDYREPACK	30 capsules	—	AB	Discontinued	—
Tamsulosin Hydrochloride .4 mg 70518-2052-00	REMEDYREPACK	90 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71205-0217-07	Proficient	7 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71205-0688-07	Proficient	7 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71335-0398-01	Bryant	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71335-1538-01	Bryant	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71335-1784-01	Bryant	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71610-0724-30	Aphena	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71610-0738-30	Aphena	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 71610-0835-30	Aphena	30 capsules	—	AB	FDA listed	—
Tamsulosin hydrochloride .4 mg 71610-0910-30	Aphena	30 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 72162-2217-05	Bryant	500 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 72162-2502-00	Bryant	1000 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 72162-2509-01	Bryant	100 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 72865-0282-01	XLCare	100 capsules	—	AB	FDA listed	—
tamsulosin hydrochloride .4 mg 72865-0350-05	XLCare	500 capsules	—	AB	FDA listed	—
Tamsulosin Hydrochloride .4 mg 68788-4145-01	Preferred	100 capsules	—	AB	FDA listed	—

About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.

Where does this data come from?

Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️

2024

On the market since

Mar 2024

📍

2026

Currently FDA-listed

2 years listed

🔓

Generic on the market

this product is a generic

✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?

Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 76282-0744-05, not the drug overall. Other pack sizes report separately.

💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.

📅 Q1 2025 – Q4 2025 · 4 quarters of data

ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.

Prescriptions last 4 qtrs

4.4K

Units reimbursed last 4 qtrs

187.4K

Gross reimbursed last 4 qtrs

$61.8K

Avg / prescription

$13.92

Avg / unit

$0.3298

Latest quarter Q4 2025

927Rx

Medicaid pays / ea

$0.3298

gross reimbursed

NADAC / ea

$0.0509

acquisition cost

Spread

+$0.2789

+548% vs cost

What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.

Fee-for-service vs managed care ⓘ

45% FFS 55% MCO

Fee-for-service · 2,014 Rx Managed care · 2,429 Rx

State Medicaid map

Units reimbursed · per 100k residents

5.31,162

gray = no data reported ⓘ

Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.

Tap or hover a state

…for its Medicaid breakdown

🏆 Top states by units · per 100k residents

1 Alaska 1,162 /100k

2 New York 337 /100k

3 South Dakota 145 /100k

4 New Jersey 127 /100k

5 Kentucky 124 /100k

6 Washington 104 /100k

7 Michigan 77.8 /100k

8 Pennsylvania 64.7 /100k

National units — by quarter

💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.

500 capsules this page76282-0744-05 4,676 Rx · $57,786

90 capsules76282-0744-90 No Medicaid data

Drug total (last 4 qtrs): 4,676 Rx · 195,663 units · $57,786 gross reimbursed

Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Tamsulosin Hydrochloride — the ingredient across all brands.

Top reported reactions

Fatigue1,552

Dyspnoea1,477

Dizziness1,307

Diarrhoea1,268

Headache991

Fall938

Asthenia923

Reporter sex

Male · 95%

Female · 5%

Unknown · 0%

Serious outcomes

Death2,262

Disabling709

Reports over time (by year) — tap or hover for the count & year

Most recent year is provisional (FAERS lags ~3 months).

Where does this data come from?

Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDC	Description	Per unit	Per pack	Marketing start	Status
76282-0744-05 You're viewing this	500 CAPSULE in 1 BOTTLE (76282-744-05)	$0.0509 / ea	$25.47	2024-03-01	Active
76282-0744-90	90 CAPSULE in 1 BOTTLE (76282-744-90)	$0.0509 / ea	$4.58	2025-03-14	Active

You're viewing the largest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0509 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 76282-0744-05?

NDC 76282-0744-05 is a 500-count package — 500 capsule in 1 bottle.

What is the difference between NDC 76282-0744-05 and NDC 76282-0744-90?

Both are Tamsulosin hydrochloride .4 mg Capsule — the drug itself is identical. NDC 76282-0744-05 is the 500-count package, while NDC 76282-0744-90 is the 90 capsules package.

What NDC number is used to bill for this package of Tamsulosin hydrochloride .4 mg Capsule?

Bill NDC 76282-0744-05 — the 11-digit billing format is 76282074405. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.

🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients

🎯 Indications and Usage 77 words ▾

1 INDICATIONS AND USAGE Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies ( 14 )]. Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia ( 1 ) Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension ( 1 )

⏱️ Dosage and Administration 216 words ▾

2 DOSAGE AND ADMINISTRATION Tamsulosin hydrochloride capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened.

For those patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing, the dose of tamsulosin hydrochloride capsules can be increased to 0.8 mg once daily. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions ( 5.2 )] . If tamsulosin hydrochloride capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.

0.4mg once daily taken approximately one-half hour following the same meal each day. Tamsulosin hydrochloride capsules should not be crushed, chewed or opened. ( 2 ) Can be increased to 0.8 mg once daily for patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing ( 2 ) If discontinued or interrupted for several days, therapy should start again with the 0.4 mg once-daily dose ( 2 )

💊 Dosage Forms and Strengths 35 words ▾

3 DOSAGE FORMS AND STRENGTHS Capsule: 0.4 mg, olive green opaque cap and an orange opaque body. The cap is imprinted with the code "TSL 0.4" in black ink. Capsules: 0.4 mg ( 3 )

⛔ Contraindications 62 words ▾

4 CONTRAINDICATIONS Tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. Reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [see Adverse Reactions ( 6.2 )]. Contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules ( 4 , 6.2 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Advise patients about the possibility of symptoms related to postural hypotension and to avoid situations where injury could result should syncope occur ( 5.1 ) Should not be used in combination with strong inhibitors of CYP3A4. Use with caution in combination with moderate inhibitors of CYP3A4, with strong or moderate inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers, or in combination with other cytochrome P450 inhibitors. ( 5.2 , 7.1 , 12.3 ) Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) Exercise caution with concomitant administration of warfarin ( 5.2 , 7.4 , 12.3 ) Advise patients about the possibility and seriousness of priapism ( 5.3 ) Intraoperative Floppy Iris Syndrome has been observed during cataract and glaucoma surgery in some patients.

Advise patients considering cataract or glaucoma surgery to tell their ophthalmologist that they have taken tamsulosin hydrochloride capsules. ( 5.5 ) Advise patients to be screened for the presence of prostate cancer prior to treatment and at regular intervals afterwards ( 5.4 )

5.1Orthostasis The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in tamsulosin hydrochloride capsule-treated patients than in placebo recipients. As with other alpha adrenergic blocking agents there is a potential risk of syncope [see Adverse Reactions ( 6.1 )] . Patients beginning treatment with tamsulosin hydrochloride capsules should be cautioned to avoid situations in which injury could result should syncope occur.

5.2Drug Interactions Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] . Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] .

Tamsulosin hydrochloride capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] . Tamsulosin hydrochloride capsules should not be used in combination with other alpha adrenergic blocking agents [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )]. Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride are coadministered with PDE5 inhibitors.

Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.3 )]. Caution should be exercised with concomitant administration of warfarin and tamsulosin hydrochloride capsules [see Drug Interactions ( 7.4 ) and Clinical Pharmacology ( 12.3 )].

5.3Priapism Rarely (probably less than 1 in 50,000 patients), tamsulosin, like other alpha 1 antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients must be advised about the seriousness of the condition.

5.4Screening for Prostate Cancer Prostate cancer and BPH frequently coexist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with tamsulosin hydrochloride capsules and at regular intervals afterwards.

5.5Intraoperative Floppy Iris Syndrome Intraoperative Floppy Iris Syndrome (IFIS) has been observed dur…

🤒 Adverse Reactions ~3 min read ▾

6 ADVERSE REACTIONS The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, nausea, sinusitis, insomnia, libido decreased, tooth disorder, and blurred vision ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Exelan Pharmaceuticals, Inc. at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S. and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg tamsulosin hydrochloride capsules were used.

These studies evaluated safety in 1783 patients treated with tamsulosin hydrochloride capsules and 798 patients administered placebo. Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men. Table 1: Treatment-Emergent * Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S.

Short-Term Placebo-Controlled Clinical Studies BODY SYSTEM/ ADVERSE EVENT TAMSULOSIN HYDROCHLORIDE CAPSULES GROUPS PLACEBO 0.4 mg n=502 0.8 mg n=492 n=493 * A treatment-emergent adverse event was defined as any event satisfying one of the following criteria: The adverse event occurred for the first time after initial dosing with double-blind study medication;The adverse event was present prior to or at the time of initial dosing with double-blind study medication and subsequently increased in severity during double-blind treatment; or The adverse event was present prior to or at the time of initial dosing with double-blind study medication, disappeared completely, and then reappeared during double-blind treatment. † Coding preferred terms also include cold, common cold, head cold, flu, and flu-like symptoms. ‡ Coding preferred terms also include nasal congestion, stuffy nose, runny nose, sinus congestion, and hay fever.

BODY AS WHOLE Headache 97 (19.3%) 104 (21.1%) 99 (20.1%) Infection † 45 (9.0%) 53 (10.8%) 37 (7.5%) Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%) Back pain 35 (7.0%) 41 (8.3%) 27 (5.5%) Chest pain 20 (4.0%) 20 (4.1%) 18 (3.7%) NERVOUS SYSTEM Dizziness 75 (14.9%) 84 (17.1%) 50 (10.1%) Somnolence 15 (3.0%) 21 (4.3%) 8 (1.6%) Insomnia 12 (2.4%) 7 (1.4%) 3 (0.6%) Libido decreased 5 (1.0%) 10 (2.0%) 6 (1.2%) RESPIRATORY SYSTEM Rhinitis ‡ 66 (13.1%) 88 (17.9%) 41 (8.3%) Pharyngitis 29 (5.8%) 25 (5.1%) 23 (4.7%) Cough increased 17 (3.4%) 22 (4.5%) 12 (2.4%) Sinusitis 11 (2.2%) 18 (3.7%) 8 (1.6%) DIGESTIVE SYSTEM Diarrhea 31 (6.2%) 21 (4.3%) 22 (4.5%) Nausea 13 (2.6%) 19 (3.9%) 16 (3.2%) Tooth disorder 6 (1.2%) 10 (2.0%) 7 (1.4%) UROGENITAL SYSTEM Abnormal ejaculation 42 (8.4%) 89 (18.1%) 1 (0.2%) SPECIAL SENSES Blurred vision 1 (0.2%) 10 (2.0%) 2 (0.4%) Signs and Symptoms of Orthostasis In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group.

Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and 0.6% of patients (3 of 493) in the placebo group. Dizziness was reported by 15% of patients (75 of 502) in the 0.4 mg group, 17% of patients (84 of 492) in the 0.8 mg group, and 10% of patients (50 of 493) in the pl…

🔄 Drug Interactions ~3 min read ▾

7 DRUG INTERACTIONS Tamsulosin hydrochloride capsules 0.4 mg should not be used with strong inhibitors of CYP3A4 (e.g., ketoconazole). Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, or in patients known to be CYP2D6 poor metabolizers, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg). ( 5.2 , 7.1 , 12.3 ) Concomitant use of PDE5 inhibitors with tamsulosin can potentially cause symptomatic hypotension ( 5.2 , 7.3 , 12.3 )

7.1Cytochrome P450 Inhibition Strong and Moderate Inhibitors of CYP3A4 or CYP2D6 Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the C max and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] . The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] .

Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the C max and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] . A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when tamsulosin hydrochloride capsules 0.4 mg are co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, tamsulosin hydrochloride capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )] .

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of tamsulosin hydrochloride capsules have not been evaluated [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )]. The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with tamsulosin hydrochloride capsules have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when tamsulosin hydrochloride capsules 0.4 mg are co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )].

Cimetidine Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of tamsulosin hydrochloride, which resulted in a moderate increase in tamsulosin hydrochloride AUC (44%) [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )].

7.2Other Alpha Adrenergic Blocking Agents The pharmacokinetic and pharmacodynamic interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between tamsulosin hydrochloride capsules and other alpha adrenergic blocking agents may be expected [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )].

7.3PDE5 Inhibitors Caution is advised when alpha adrenergic blocking agents including tamsulosin hydrochloride capsules are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 )].

7.4Warfarin A definitive drug-drug interaction study between tamsulosin hydrochloride and warfarin was not conducted. Results from limited in vitro and in viv…

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Pediatric Use: Not indicated for use in pediatric populations ( 8.4 , 12.3 ) Geriatric Use: No overall differences in efficacy or safety vs younger patients, but greater sensitivity of some older adults cannot be ruled out ( 8.5 , 12.3 ) Renal Impairment: Has not been studied in patients with end-stage renal disease ( 8.6 , 12.3 ) Hepatic Impairment: Has not been studied in patients with severe hepatic impairment ( 8.7 , 12.3 )

8.1Pregnancy Risk Summary Tamsulosin hydrochloride capsules are not indicated for use in women. There are no adequate data on the developmental risk associated with the use of tamsulosin hydrochloride capsules in pregnant women. No adverse developmental effects were observed in animal studies in which tamsulosin hydrochloride was administered to rats or rabbits during the period of organogenesis (GD 7 to 17 in the rat and GD 6 to 18 in the rabbit) [see Data] .

In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Data Administration of tamsulosin hydrochloride to pregnant female rats during the period of organogenesis at dose levels up to approximately 50 times the human therapeutic AUC exposure (300 mg/kg/day) revealed no evidence of harm to the fetus. Administration of tamsulosin hydrochloride to pregnant rabbits during the period of organogenesis at dose levels up to 50 mg/kg/day produced no evidence of fetal harm.

8.2Lactation Tamsulosin hydrochloride capsules are not indicated for use in women. There are no data on the presence of tamsulosin hydrochloride in human milk, the effects of tamsulosin hydrochloride on the breastfed infant, or the effects of tamsulosin hydrochloride on milk production. Tamsulosin hydrochloride is present in the milk of lactating rats [see Data] .

Data Oral administration of radiolabeled tamsulosin hydrochloride to rats demonstrated that tamsulosin hydrochloride and/or its metabolites are excreted into the milk of rats.

8.3Females and Males of Reproductive Potential Infertility Males Abnormal ejaculation including ejaculation failure, ejaculation disorder, retrograde ejaculation, and ejaculation decrease has been associated with tamsulosin hydrochloride capsules [see Adverse Reactions ( 6.1 )]. Studies in rats revealed significantly reduced fertility in males considered to be due to impairment of ejaculation, which was reversible [see Nonclinical Toxicology ( 13.1 )] . Females Tamsulosin hydrochloride capsules are not indicated for use in women.

Female fertility in rats was significantly reduced, considered to be due to impairment of fertilization [see Nonclinical Toxicology ( 13.1 )].

8.4Pediatric Use Tamsulosin hydrochloride capsules are not indicated for use in pediatric populations. Efficacy and positive benefit/risk of tamsulosin hydrochloride was not demonstrated in two studies conducted in patients 2 years to 16 years of age with elevated detrusor leak point pressure (>40 cm H2 O) associated with known neurological disorder (e.g., spina bifida). Patients in both studies were treated on a weight-based mg/kg schema (0.025 mg, 0.05 mg, 0.1 mg, 0.2 mg, or 0.4 mg tamsulosin hydrochloride) for the reduction in detrusor leak point pressure below 40 cm H 2 O.

In a randomized, double-blind, placebo-controlled, 14-week, pharmacokinetic, safety and efficacy study in 161 patients, no statistically significant difference in the proportion of responders was observed between groups receiving tamsulosin hydrochloride and placebo. In an open-label, 12-month safety study, 87 patients were treated with tamsulosin hydrochloride. The most frequently reported adverse events (≥5%) from the pooled data of both studies were urinary tract infection, vomiting, pyrexia, headache, nasopharyngitis, cough, pharyngitis, influenza, diarrhea, abdominal pain, and constipation.

8.5 Geriatric Use Of the total number of subjects (1783) in clinical s…

🤰 Pregnancy 163 words ▾

🧒 Pediatric Use 168 words ▾

🧓 Geriatric Use 73 words ▾

8.5Geriatric Use Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology ( 12.3 )].

🆘 Overdosage 104 words ▾

10 OVERDOSAGE Should overdosage of tamsulosin hydrochloride capsules lead to hypotension [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] , support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered.

If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that tamsulosin hydrochloride is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate.

The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha1 adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH.

Tamsulosin, an alpha 1 adrenoceptor blocking agent, exhibits selectivity for alpha1 receptors in the human prostate. At least three discrete alpha 1 adrenoceptor subtypes have been identified: alpha 1A , alpha 1B , and alpha 1D ; their distribution differs between human organs and tissue. Approximately 70% of the alpha 1 receptors in the human prostate are of the alpha 1A subtype.

Tamsulosin hydrochloride capsules are not intended for use as an antihypertensive drug.

12.2Pharmacodynamics Urologic pharmacodynamic effects have been evaluated in neurologically impaired pediatric patients and in adults with BPH [see Use in Specific Populations ( 8.4 ) and Clinical Studies ( 14 )].

12.3Pharmacokinetics The pharmacokinetics of tamsulosin hydrochloride have been evaluated in adult healthy volunteers and patients with BPH after single and/or multiple administration with doses ranging from 0.1 mg to 1 mg. Absorption Absorption of tamsulosin hydrochloride from tamsulosin hydrochloride capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions. Tamsulosin hydrochloride exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-a-day dosing.

Effect of Food The time to maximum concentration (T max ) is reached by 4 to 5 hours under fasting conditions and by 6 to 7 hours when tamsulosin hydrochloride capsules are administered with food. Taking tamsulosin hydrochloride capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (C max ) compared to fed conditions (Figure 1). Figure 1: Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) The effects of food on the pharmacokinetics of tamsulosin hydrochloride are consistent regardless of whether a tamsulosin hydrochloride capsule is taken with a light breakfast or a high-fat breakfast (Table 2).

Table 2: Mean (± S.D.) Pharmacokinetic Parameters Following Tamsulosin Hydrochloride Capsules 0.4 mg Once Daily or 0.8 mg Once Daily with a Light Breakfast, High-Fat Breakfast or Fasted Pharmacokinetic Parameter 0.4 mg QD to healthy volunteers; n=23 (age range 18–32 years) 0.8 mg QD to healthy volunteers; n=22 (age range 55–75 years) Light Breakfast Fasted Light Breakfast High-Fat Breakfast Fasted C min = observed minimum concentration C max = observed maximum tamsulosin hydrochloride plasma concentration T max = median time-to-maximum concentration T 1/2 = observed half-life AUC τ = area under the tamsulosin hydrochloride plasma time curve over the dosing interval C min (ng/mL) 4.0 ± 2.6 3.8 ± 2.5 12.3 ± 6.7 13.5 ± 7.6 13.3 ±

13.3C max (ng/mL) 10.1 ± 4.8 17.1 ± 17.1 29.8 ± 10.3 29.1 ± 11.0 41.6 ±

15.6C max /C min Ratio 3.1 ± 1.0 5.3 ± 2.2 2.7 ± 0.7 2.5 ± 0.8 3.6 ±

1.1T max (hours) 6.0 4…

🧬 Mechanism of Action ~1 min read ▾

Tamsulosin hydrochloride capsules are not intended for use as an antihypertensive drug.

📦 How Supplied / Storage and Handling 86 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Tamsulosin hydrochloride capsules USP, 0.4 mg are supplied in high density polyethylene bottles containing 90, 500 hard gelatin capsules with an olive green opaque cap and an orange opaque body. The cap is imprinted with the code “TSL 0.4” in black ink. Bottle of 90 capsules (NDC 76282-744-90) Bottle of 500 capsules (NDC 76282-744-05) Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F) [see USP Controlled Room Temperature].

Keep tamsulosin hydrochloride capsules, USP and all medicines out of reach of children.

📋 Description 155 words ▾

11 DESCRIPTION Tamsulosin hydrochloride is an antagonist of alpha 1A adrenoceptors in the prostate. Tamsulosin hydrochloride is (-)-( R)-5-[2-[[2-( o-Ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride. Tamsulosin hydrochloride is a white crystalline powder that melts with decomposition at approximately 230°C.

It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether. The empirical formula of tamsulosin hydrochloride is C20H28N2O5S ∙ HCl. The molecular weight of tamsulosin hydrochloride is 444.98.

Its structural formula is: Each tamsulosin hydrochloride capsule for oral administration contains tamsulosin hydrochloride, USP 0.4 mg, and the following inactive ingredients: methacrylic acid copolymer, microcrystalline cellulose, purified water, talc, triethyl citrate, black iron oxide, FD&C Blue No. 2, gelatin, red iron oxide, titanium dioxide, yellow iron oxide and trace amounts of antifoam DC 1510, industrial methylated spirit, lecithin, n-butyl alcohol, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, ammonium, potassium hydroxide and shellac.

Complies with USP Dissolution Test 4. Str.

💬 Information for Patients ~3 min read ▾

PATIENT INFORMATION Tamsulosin hydrochloride capsules USP, 0.4 mg (tam soo' loe sin hye'' droe klor' ide) Read the Patient Information that comes with tamsulosin hydrochloride capsules before you start taking it and each time you refill your prescription. The information may have changed. This leaflet does not take the place of discussions with your doctor about your medical condition or your treatment.

What are Tamsulosin hydrochloride capsules? Tamsulosin hydrochloride capsules are a prescription alpha-blocker medicine used to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition your doctor may refer to as an enlarged prostate. Tamsulosin hydrochloride capsules are not for women.

Tamsulosin hydrochloride capsules are not for children. Who should not take Tamsulosin hydrochloride capsules? Do not take tamsulosin hydrochloride capsules if you are allergic to any of its ingredients.

See the end of this leaflet for a complete list of ingredients in tamsulosin hydrochloride capsules. What should I tell my doctor before using tamsulosin hydrochloride capsules? Before taking tamsulosin hydrochloride capsules, tell your doctor about all your medical conditions, including: any kidney or liver problems. any history of low blood pressure. any allergies to sulfa or any other medicines. if you are planning to have cataract or glaucoma surgery.

Tell your doctor about all the medicines you take, including: any prescription medicines, including blood pressure medicines. any non-prescription medicines, including vitamins and herbal supplements. Some of your other medicines may affect the way tamsulosin hydrochloride capsules work. Especially tell your doctor if you take a medicine for high blood pressure.

You should not take tamsulosin hydrochloride capsules if you are already taking certain blood pressure medicines. Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

How should I take tamsulosin hydrochloride capsules? Take tamsulosin hydrochloride capsules exactly as prescribed by your doctor. Do not crush, chew, or open tamsulosin hydrochloride capsules.

Take tamsulosin hydrochloride capsules one time each day, about 30 minutes after the same meal each day. For example, you may take tamsulosin hydrochloride capsules 30 minutes after dinner each day. If you miss a dose of tamsulosin hydrochloride capsules, take it as soon as you remember.

If you miss your dose for the whole day, continue with your next dose on your regular schedule. Do not take two doses at the same time. If you stop or forget to take tamsulosin hydrochloride capsules for several days, talk with your doctor before starting again.

If you take more tamsulosin hydrochloride capsules than prescribed, call your doctor right away. What are the possible side effects of tamsulosin hydrochloride capsules? Possible side effects of tamsulosin hydrochloride capsules may include: Decreased blood pressure when changing positions .Tamsulosin hydrochloride capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses.

Symptoms may include: fainting dizziness lightheadedness Change positions slowly from lying down to sitting up or from a sitting to a standing position until you learn how you react to tamsulosin hydrochloride capsules. If you begin to feel dizzy, sit or lie down until you feel better. If the symptoms are severe or do not improve, call your doctor.

Allergic reactions. Make your doctor aware of any allergic reactions you may experience while taking tamsulosin hydrochloride capsules. Allergic reactions may include: rash itching hives Rare and more serious allergic reactions may also occur.

Get medical help right away if you have any of the following reactions: swelling of face, tongue, or throat difficulty breathing blistering of the skin A painful erection that will not go away. Tamsulosin hydrochloride capsules can cause a…

Glossary — plain-language definitions of medical terms used in this label:

contraindicated: Should not be used in that situation, because the risk is considered too high.

in vitro: In a laboratory dish or test tube rather than in a living person or animal; results may not carry over to people.

abdominal pain: Pain, cramping, or discomfort felt anywhere in the belly area.

Absorption: How a medicine moves from where it is taken, such as the stomach or gut, into the bloodstream.

adverse event: Any unwanted medical problem that happens during treatment, whether or not the medicine actually caused it.

Adverse Reactions: Unwanted or harmful effects that people experienced while taking a medicine, listed on its official label.

angioedema: Rapid swelling deep under the skin, often around the eyes, lips, tongue, or throat.

antagonist: A substance that blocks a target in the body so a natural signal or another medicine cannot produce its usual effect.

asthenia: Unusual weakness or lack of physical strength and energy.

AUC: A measure of total drug exposure over time, showing how much medicine the blood is exposed to overall.

Bioavailability: The share of a dose that actually reaches the bloodstream and is able to have an effect.

cataract: A clouding of the eye's normally clear lens that can blur or dim vision.

clearance: How quickly the body removes a medicine from the blood, usually through the liver and kidneys.

Clinical Pharmacology: The label section explaining how a medicine works in the body and how the body processes it.

Clinical Studies: The label section summarizing the research trials used to show that a medicine works and is acceptably safe.

constipation: Having bowel movements less often than usual, or passing stools that are hard, dry, and difficult to move.

Contraindications: A list of situations or health conditions in which a medicine should not be used because the chance of harm is too high.

CYP2D6: A liver enzyme that breaks down many medicines; people inherit different versions, so it works faster in some and slower in others.

CYP3A4: One of the most important liver and gut enzymes, responsible for breaking down a large share of all medicines.

cytochrome P450: A large family of enzymes, mostly in the liver, that break down many medicines so the body can remove them.

diarrhea: Loose, watery bowel movements that happen more often than normal.

Distribution: How a medicine spreads from the blood into the body's tissues and organs after it is absorbed.

Dosage and Administration: The label section explaining how much of a medicine to use and how to take or give it.

double-blind: A study in which neither the patients nor their doctors know who is getting the real medicine and who is getting the dummy.

Drug Interactions: The label section listing other medicines, foods, or substances that can change how a medicine works or raise the chance of side effects.

efficacy: How well a treatment works under the controlled conditions of a clinical study.

end-stage renal disease: The most advanced, permanent stage of kidney failure, usually needing dialysis or a kidney transplant.

estimated background risk: The normal chance that any pregnancy will have a birth defect or problem, even without taking any medicine.

fertility: The natural ability to become pregnant or to father a child.

fetal harm: Injury or damage to a developing baby while it is growing inside the womb.

glaucoma: An eye condition, often linked to high pressure inside the eye, that can slowly damage vision.

Half-life: The time it takes for the amount of medicine in the blood to drop by half.

hepatic impairment: Reduced liver function, meaning the liver does not work as well as normal at processing substances, including medicines.

How Supplied/Storage and Handling: The label section describing the forms and strengths a medicine comes in and how to store it properly.

hypertension: Blood pressure that stays higher than normal, commonly called high blood pressure.

hypotension: Blood pressure that is lower than normal, which can cause dizziness or fainting.

incidence: How often a new event, such as a side effect, happens in a group of people over a set period of time.

Indications and Usage: The label section stating which medical conditions the FDA has officially approved the medicine to treat, prevent, or manage.

inhibitor: A substance that blocks an enzyme or transporter, which can raise the levels of drugs it normally handles.

insomnia: Trouble falling asleep, staying asleep, or getting restful sleep.

intravenous: Given directly into a vein through a needle or thin tube; often written as IV.

lactation: The making and release of milk from a mother's breasts after giving birth.

Mechanism of Action: How a medicine produces its effect in the body, described at the level of cells or body chemistry.

nasopharyngitis: Inflammation of the nose and throat, commonly known as the common cold.

NDC: A unique number that identifies a specific medicine, its maker, strength, and package size.

Nonclinical Toxicology: The label section summarizing safety findings from laboratory and animal studies, rather than from studies in people.

open-label: A study in which both the patients and their doctors know which treatment each person is receiving.

organogenesis: The early stage of pregnancy when the developing baby's organs are first forming.

Overdosage: The label section describing what can happen if too much of a medicine is taken and how it may be treated.

Pharmacokinetics: The study of how the body takes in a medicine, spreads it around, breaks it down, and removes it over time.

placebo: An inactive treatment with no real medicine in it, such as a sugar pill, used for comparison in a study.

placebo-controlled: Describes a study that compares people taking the real medicine against people taking a dummy pill with no active ingredient.

plasma concentration: The amount of medicine measured in the liquid part of the blood at a given time.

pruritus: Itching of the skin.

pyrexia: A raised body temperature; a fever.

randomized: Assigned to a treatment group purely by chance, like a coin flip, so the groups being compared start out fair and similar.

renal impairment: Reduced kidney function, meaning the kidneys do not filter waste and fluid from the blood as well as normal.

reproductive potential: The ability to have children, meaning a person who could become pregnant or could father a child.

somnolence: Feeling very sleepy or drowsy, with trouble staying awake during the day.

statistically significant: A result unlikely to be due to chance alone, suggesting a real difference between the groups being compared.

strong inhibitor: A substance that blocks an enzyme very powerfully, causing a large rise in the levels of affected drugs.

syncope: The medical term for fainting, a brief loss of consciousness from a temporary drop in blood flow to the brain.

treatment-emergent: Describes a side effect that first appears, or gets worse, after a person starts taking a treatment.

urticaria: Raised, itchy welts on the skin, commonly called hives.

Use in Specific Populations: The label section describing how a medicine affects particular groups, such as pregnant people, children, or older adults.

vertigo: A spinning sensation that makes you feel like you or the room around you is moving.

Warnings and Precautions: The label section describing serious risks to know about and safety steps to follow while using a medicine.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

← 76282-0740-30 · Exelan 76282-0755-60 · EXELAN →

For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.

Tamsulosin hydrochloride .4 mg Capsule, 500-count

🆔 Identity & classification

🏷️ RxNorm drug class

🏭 Manufacturer & labeler

🩺 Clinical

Patient education

Supplement & herbal interactions

💊 What it looks like

🧪 Inactive Ingredients / Excipients

Inactive ingredient FAQ

💲 Pricing

🔁 Therapeutic equivalents

⏳ Availability & generic status

🗺️ Medicaid utilization & spend

💊 Medicaid utilization by pack size

🔬 Reported adverse events (FAERS)

Top reported reactions

Reporter sex

Serious outcomes

📦 Packaging — all sizes for this product

Pack size FAQ

📄 Full prescribing information FDA SPL

8.5 Geriatric Use Of the total number of subjects (1783) in clinical s…

12 CLINICAL PHARMACOLOGY

🔗 Related NDC lookups

💊 Related drugs in this class